Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

Strategies to Increase Adalimumab Biosimilar Uptake in Clinical Practice

April 19th 2024

By Jamie T. Brogan, MSN, APRN, FNP-BC

Video

A clinical pharmacist and specialists in rheumatology, dermatology, and gastrointestinal disease share strategies in how to increase the uptake of adalimumab biosimilar among providers.

The Top 5 Biosimilar Articles for the Week of April 15

April 19th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of April 15, 2024.

Julie Reed: Why 2024 Is Important for Biosimilars

April 17th 2024

By Skylar Jeremias

Article

Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.

Fresenius Kabi's Tocilizumab Biosimilar, Tyenne, Launches in US Market

April 16th 2024

By Rose McNulty

Article

Tyenne (tocilizumab-aazg) was the second tocilizumab biosimilar to be FDA approved, but it is the first to launch in the US.

Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval

April 16th 2024

By Skylar Jeremias

Article

Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.

The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability

April 16th 2024

By Skylar Jeremias

Article

Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.

BioRationality: Removing the Misconceptions Surrounding Interchangeability

April 15th 2024

By Sarfaraz K. Niazi, PhD

Article

Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.

Sintilimab, Bevacizumab Biosimilar, HAIC Improves Survival in Patients With Unresectable HCC

April 14th 2024

By Cameron Santoro

Article

Positive results of sintilimab, IBI305, and hepatic arterial infusion chemotherapy (HAIC) treatment showed shrinking tumors and previously converting inoperable hepatocellular carcinoma (HCC) to resectable HCC with manageable adverse effects.

What Clinicians Need to Know About Using Biosimilars to Treat IBD

April 13th 2024

By Deana Ferreri, PhD

Article

A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.

The Role of Pharmacy Benefit Managers and Payers in Accessing Adalimumab Biosimilars

April 12th 2024

By Jamie T. Brogan, MSN, APRN, FNP-BC

Video

A clinical pharmacist discusses the role of pharmacy benefit managers and payers in accessibility of adalimumab biosimilars.